Stock of the Day

Vera Therapeutics (VERA)

$21.30

-$9.33 (-30.5%)

Market Cap: $1.39B

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Recent News

• Scotiabank Increases the Price Target for Vera Therapeutics by $10 (msn.com)
• Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (globenewswire.com)
• Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) (seekingalpha.com)
• Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 (msn.com)
• Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans (msn.com)
• Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (finance.yahoo.com)
• Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (globenewswire.com)
• Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (msn.com)
• Vera Therapeutics Shares Climb on Positive Trial Results for Kidney Disease Drug (marketwatch.com)
• Vera Therapeutics Shares Jump 80% on Strong Phase 3 Trial Results for Atacicept (msn.com)